Recurrent or Metastatic Breast Cancer

Oncology·MeSH: Recurrence

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

5 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Compare drugs

cerianna vs Eribulincerianna vs Eribulin Mesylatecerianna vs SYS6010

Frequently asked questions

How many drugs are in development for Recurrent or Metastatic Breast Cancer?

BioSniper tracks 5 drugs in development for Recurrent or Metastatic Breast Cancer across 2 companies.

How many clinical trials target Recurrent or Metastatic Breast Cancer?

There are 2 clinical trials targeting Recurrent or Metastatic Breast Cancer tracked by BioSniper.

What is the prevalence of Recurrent or Metastatic Breast Cancer?

The estimated prevalence of Recurrent or Metastatic Breast Cancer is approximately 287.0 per 100,000 population.

Deep-dive into Recurrent or Metastatic Breast Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Recurrent or Metastatic Breast Cancer — Drugs in Development & Clinical Trials | BioSniper